Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults

Hassen Kared, Asia-Sophia Wolf, Amin Alirezaylavasani, Anthony Ravussin, Guri Solum, Trung The Tran, Fridtjof Lund-Johansen, John Torgils Vaage, Lise Sofie Nissen-Meyer, Unni C. Nygaard, Olav Hungnes, Anna H Robertson, Lisbeth Meyer Næss, Lill Trogstad, Per Magnus, Ludvig A Munthe, Siri Mjaaland
doi: https://doi.org/10.1101/2022.01.13.22269213
Hassen Kared
1KG Jebsen Centre for B cell malignancy, Institute of Clinical medicine, University of Oslo
2Department of Immunology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hassen.kared{at}medisin.uio.no l.a.munthe{at}medisin.uio.no
Asia-Sophia Wolf
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin Alirezaylavasani
1KG Jebsen Centre for B cell malignancy, Institute of Clinical medicine, University of Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Ravussin
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guri Solum
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trung The Tran
2Department of Immunology, Oslo University Hospital, Oslo, Norway
4ImmunoLingo Convergence Center, Institute of Clinical medicine, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fridtjof Lund-Johansen
2Department of Immunology, Oslo University Hospital, Oslo, Norway
4ImmunoLingo Convergence Center, Institute of Clinical medicine, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Torgils Vaage
2Department of Immunology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lise Sofie Nissen-Meyer
2Department of Immunology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Unni C. Nygaard
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olav Hungnes
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna H Robertson
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisbeth Meyer Næss
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lill Trogstad
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Magnus
5Center for Fertility and Health, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludvig A Munthe
1KG Jebsen Centre for B cell malignancy, Institute of Clinical medicine, University of Oslo
2Department of Immunology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hassen.kared{at}medisin.uio.no l.a.munthe{at}medisin.uio.no
Siri Mjaaland
3Division of Infection Control, Norwegian Institute of Public Health, Oslo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The new SARS-CoV-2 variant of concern (VOC) Omicron has more than 30 mutations in the receptor binding domain (RBD) of the Spike protein enabling viral escape from antibodies in vaccinated individuals and increased transmissibility1-6. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a superspreader event had robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. We compared cases from a Christmas party where 81 of 110 (74%) developed Omicron breakthrough COVID-197, with Delta breakthrough cases and vaccinated non-infected controls. Omicron cases had significantly increased activated SARS-CoV-2 wild type Spike-specific (vaccine) cytotoxic T cells, activated follicular helper (TFH) cells, functional T cell responses, boosted humoral responses, activated anti-Spike plasmablasts and anti-RBD memory B cells compared to controls. Omicron cases had significantly increased de novo memory T cell responses to non-Spike viral antigens compared to Delta breakthrough cases demonstrating development of broad immunity. The rapid release of Spike and RBD-specific IgG+ B cell plasmablasts and memory B cells into circulation suggested affinity maturation of antibodies and that concerted T and B cell immunity may provide durable broad immunity.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Norwegian Institute of Public Health, the Norwegian Ministry of Health through a programme for corona vaccination surveillance, the Research Council of Norway (RCN) Covid (312693); a KG Jebsen Foundation (grant 19); the Coalition for Epidemic Preparedness Innovations (CEPI); and the University of Oslo and Oslo University Hospital.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approvals have been obtained from the Regional Ethics Authority, South Eastern Norway

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 13, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
Hassen Kared, Asia-Sophia Wolf, Amin Alirezaylavasani, Anthony Ravussin, Guri Solum, Trung The Tran, Fridtjof Lund-Johansen, John Torgils Vaage, Lise Sofie Nissen-Meyer, Unni C. Nygaard, Olav Hungnes, Anna H Robertson, Lisbeth Meyer Næss, Lill Trogstad, Per Magnus, Ludvig A Munthe, Siri Mjaaland
medRxiv 2022.01.13.22269213; doi: https://doi.org/10.1101/2022.01.13.22269213
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
Hassen Kared, Asia-Sophia Wolf, Amin Alirezaylavasani, Anthony Ravussin, Guri Solum, Trung The Tran, Fridtjof Lund-Johansen, John Torgils Vaage, Lise Sofie Nissen-Meyer, Unni C. Nygaard, Olav Hungnes, Anna H Robertson, Lisbeth Meyer Næss, Lill Trogstad, Per Magnus, Ludvig A Munthe, Siri Mjaaland
medRxiv 2022.01.13.22269213; doi: https://doi.org/10.1101/2022.01.13.22269213

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)